References
- Mir O, Ropert S, Alexandre J, Goldwasser F. Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 2009;20:967–70.
- Rini BI, Cohen DP, Lu DR, Chen I, Hariharan S, Gore ME, et al. Hypertension as a biomarker of efficacy in patients with metastastic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011;103:763–73.
- Humar R, Zimmerli L, Battegay E. Angiogenesis and hypertension: An update. J Hum Hypertens 2009;23:773–82.
- Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96: 1788–95.
- Jubb A, Harris A. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010;11:1172–83.
- Bono P, Elfving H, Utriainen T, Osterlund P, Saarto T, Alanko T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009;20:393–4.
- Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227–30.
- Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327.
- Schuster C, Eikesdal HP, Puntervoll H, Geisler J, Geisler S, Heinrich D, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: Predictive importance of induced early hypertension. PLos One 2012;7:e38364.
- Wick A, Schäfer N, Dörner N, Schemmer D, Platten M, Bendszus M, et al. Arterial hypertension and bevacizumab treatment in glioblastoma: No correlation with clinical outcome. J Neurooncol 2010;97:157–8.
- Lombardi G, Zustovich F, Farina P, Fiduccia P, Della Puppa A, Polo V, et al. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: A single-center experience and a critical review of the literature. Anticancer Drugs 2013;24:90–7.
- Development Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, Available from: http://www.R-project.org/ [cited 2013 Oct 29].
- Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27: 4733–40.
- Wick W, Cloughesy TF, Nishikawa R, Mason W, Saran F, Henriksson R, et al. Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression in the phase III AVAglio trial of bevacizumab plus temozolomide plus radiotherapy in newly diagnosed glioblastoma patients. Proc Am Soc Clin Oncol 2013;31 (Suppl Abstract 2002).
- Deshayes F, Nahmias C. Angiotensin receptors: A new role in cancer?Trends Endocrinol Metab 2005;16:293–9.
- Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ, et al. Antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007;204:996–1006.